Home > Boards > US Listed > Biotechs > Cytokinetics, Inc. (CYTK)

Some Notable Items (easier with the transcript :)

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
H2R Member Profile
 
Followed By 25
Posts 1,833
Boards Moderated 0
Alias Born 07/17/14
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/4/2021 4:58:40 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/4/2021 4:58:13 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/4/2021 4:58:07 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/4/2021 4:57:56 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/4/2021 4:57:47 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/4/2021 4:57:34 PM
Cytokinetics to Participate in Upcoming Investor Conferences GlobeNewswire Inc. - 3/2/2021 4:00:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/1/2021 5:06:42 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/1/2021 5:05:32 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/1/2021 5:02:20 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/1/2021 6:06:59 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/26/2021 6:25:43 PM
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. - 2/26/2021 4:32:36 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/26/2021 7:30:58 AM
Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day GlobeNewswire Inc. - 2/26/2021 7:30:00 AM
Cytokinetics EPS misses by $0.13, misses on revenue Seeking Alpha - 2/25/2021 4:19:04 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/25/2021 4:01:19 PM
Cytokinetics Reports Fourth Quarter 2020 Financial Results GlobeNewswire Inc. - 2/25/2021 4:00:00 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/19/2021 5:03:28 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/19/2021 4:20:34 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/18/2021 7:30:59 AM
Cytokinetics Names Muna Bhanji to Board of Directors GlobeNewswire Inc. - 2/18/2021 7:30:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/16/2021 3:17:35 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/12/2021 6:39:21 PM
Cytokinetics to Announce Fourth Quarter Results on February 25, 2021 GlobeNewswire Inc. - 2/11/2021 4:00:00 PM
H2R   Friday, 10/27/17 10:22:19 AM
Re: None
Post # of 1503 
Some Notable Items (easier with the transcript :)

https://seekingalpha.com/article/4117162-cytokinetics-cytk-ceo-robert-blum-q3-2017-results-earnings-call-transcript?part=single

1-
Quote:
The results of VITALITY-ALS have been accepted for presentation by our lead investigator Dr. Jeremy Shefner at the International Symposium on ALS/MND on December 8th at 4:20 p.m. in Boston.


If data is available, they will have a big echo chamber to announce the results (hopefully, the positive results). That's only a month and some away! CYTK is optimistic but anything can happen, they need to see the final data of course.

2 -
Quote:
more than 90% of patients who have completed VITALITY-ALS have left into enrolled into VIGOR-ALS to open-label expansion for patient to complete the treatment in VITALITY-ALS. A particular note with this participation in VIGOR-ALS, some patients now has been on tirasemtiv for nearly two years.


If those patients did not see any benefits, would they continue on the open-label? Would they be on tirasemtiv for two years?

3 - Lots of updates on other trials to be announced over the course of 2018

4 -
Quote:
CK-107 can improve muscle function, exercise performance, and stamina, maybe it will preserve aging person’s ability to perform tasks and maintain independence.


The market will include the 'aging population'! That's, what's the word ..., Huge!

5 -
Quote:
we ended the third quarter with $308 million in cash, cash equivalents and investments represents over 24 months of going for cash burn based on our 2017 financial guidance.


Strong financial situation + strong partners: They will not be the object of the typical biotech short attacks or if they are, they are very well position to resist those. And they may have enough cash to get to a commercial stage if tirasemtiv is approved, say, late 2018, early 2019. They are in a very good position.

6 - They have a strategy in case tirasemtiv is a failure to reallocate resources to other trials. A failure would be hard for the company, but I like the fact that they are thinking about how to continue in this case. It's rare you hear those plans from a biotech. It also shows the strength of their pipeline!

I like the upcoming catalyst being about a month away, the optimistic note around the Ph III, the cash position, and the pipeline. I bought a few more shares today.



Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences